Valuation: AstraZeneca Pharma India Limited

Market Cap 194B 2.01B 1.76B 1.62B 1.5B 2.82B 2.88B 19.42B 7.64B 95.01B 7.56B 7.4B 327B P/E 2024
82.4x
P/E 2025 186x
Enterprise Value 189B 1.96B 1.71B 1.58B 1.46B 2.75B 2.81B 18.91B 7.44B 92.56B 7.37B 7.21B 319B EV / Sales 2024
9.88x
EV / Sales 2025 12.2x
Free-Float
18.42%
Yield 2024
0.45%
Yield 2025 0.37%
1 day-0.82%
1 week-1.21%
Current month-2.31%
1 month-5.74%
3 months-5.67%
6 months-2.74%
Current year-10.92%
1 week 8,021
Extreme 8021
8,399
1 month 7,945
Extreme 7945
8,766.35
Current year 7,630
Extreme 7630
9,219.25
1 year 7,630
Extreme 7630
9,850
3 years 3,730
Extreme 3730
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 2025-06-30
Director of Finance/CFO - 2023-09-30
Compliance Officer - 2026-02-22
Director TitleAgeSince
Director/Board Member 67 2016-12-01
Chairman 52 2024-09-29
Director/Board Member - 2024-02-07
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-1.21%-11.91%+112.37% 2.08B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.14%+0.36%+24.49%+59.76% 357.71B
Weighted average by Cap. +0.37%+0.02%+37.48%+79.65%

Financials

2024 2025
Net sales 12.96B 135M 118M 108M 100M 188M 193M 1.3B 510M 6.34B 505M 494M 21.84B 17.16B 178M 156M 144M 132M 250M 255M 1.72B 676M 8.41B 669M 655M 28.94B
Net income 1.62B 16.77M 14.66M 13.52M 12.47M 23.5M 24.02M 162M 63.58M 791M 62.98M 61.6M 2.72B 1.16B 12.02M 10.5M 9.69M 8.93M 16.84M 17.21M 116M 45.56M 567M 45.14M 44.15M 1.95B
Net Debt -5.01B -52.02M -45.46M -41.95M -38.67M -72.88M -74.5M -501M -197M -2.45B -195M -191M -8.45B -5B -51.96M -45.41M -41.9M -38.62M -72.8M -74.42M -501M -197M -2.45B -195M -191M -8.44B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
600
Date Price Change Volume
26-07-17 ₹8,025.95 -0.82% 1,060
26-07-16 ₹8,092.00 -1.77% 737
26-07-15 ₹8,237.40 +0.64% 273
26-07-14 ₹8,185.10 -1.04% 227
26-07-13 ₹8,271.35 +1.82% 2,246
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock